MS

Manikanta Surya Pradeep Kruthiventi

Active Director Director DIN 11538149
DIN 11538149 First appointment Feb 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Manikanta Surya Pradeep Kruthiventi

Data last updated:

Manikanta Surya Pradeep Kruthiventi is a Director at Rook Pharmaceuticals Private Limited (since 2026). The company operates in Pharma.

DIN 11538149
Primary Designation Director
Industry Pharma
First Appointment 11 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rook Pharmaceuticals Private Limited U21001TS2026PTC211096
Director11 Feb 20262026Active

Board colleagues of Manikanta Surya Pradeep Kruthiventi

Directorship timeline

Open interactive timeline →
Rook Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manikanta Surya Pradeep Kruthiventi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manikanta Surya Pradeep Kruthiventi

Manikanta Surya Pradeep Kruthiventi currently holds 1 directorship: Rook Pharmaceuticals Private Limited (Director, since 11 Feb 2026).

Manikanta Surya Pradeep Kruthiventi was first appointed on 11 Feb 2026 as Director at Rook Pharmaceuticals Private Limited.

The current boards of Manikanta Surya Pradeep Kruthiventi's companies include Ramabhadram Gadi (Rook Pharmaceuticals Private Limited), Srinivas Rayala (Rook Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available